Press release
Duchenne Muscular Dystrophy Pipeline Assessment (2023 Updates) | In-depth Insights into the Clinical Trials, Emerging Drugs, Latest FDA, EMA, and PMDA Approvals, Competitive Landscape, and Treatment Outlook | Key Companies - Sarepta, Bioleaders Corporatio
"Duchenne Muscular Dystrophy Pipeline Insight, 2023" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Duchenne Muscular Dystrophy Therapeutics Market.
The report provides a detailed description of the drug, including the mechanism of action, type, stage, route of administration, molecule type, clinical studies, inactive pipeline products, and NDA approvals (if any). The report also covers commercial and clinical activities of the pipeline products from the pre-clinical developmental phase to the marketed stage. Additionally, it presents the ongoing developments in the therapeutics segment, including collaborations, licensing, mergers & acquisitions (M&A), funding, designations, and other product-related details.
Duchenne Muscular Dystrophy Pipeline Analysis
The report provides insights into:
• The report provides detailed insights into the key companies that are developing therapies in the Duchenne Muscular Dystrophy Market.
• The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Duchenne Muscular Dystrophy treatment.
• It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• It navigates the emerging drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the Duchenne Muscular Dystrophy market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Learn More about the Clinical and Commercial Development Activities in the Duchenne Muscular Dystrophy Therapeutics Domain:
https://www.delveinsight.com/report-store/duchenne-muscular-dystrophy-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr
The Report Covers the Emerging Pipeline Products Under Different Phases of Clinical Development Like -
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
Route of Administration
Duchenne Muscular Dystrophy pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
• Oral
• Intravenous
• Subcutaneous
Molecule Type
Products have been categorized under various Molecule types, such as
• Small molecule
• Cell Therapy
• Peptides
• Polymer
• Small molecule
• Gene therapy
Mechanism of Action of the Emerging Pipeline Therapies
• Dipeptidyl peptidase I inhibitors
• Peroxisome proliferator-activated receptor delta modulators
• Cell replacements
• Dystrophin expression stimulants
• Connective tissue growth factor inhibitors
• Dystrophin replacements
• Immunostimulants
• Gene modulators
• Dystrophin expression modulators
Request for Sample PDF to Understand More About the Treatment Outlook and Future Perspectives:
https://www.delveinsight.com/sample-request/duchenne-muscular-dystrophy-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr
Duchenne Muscular Dystrophy Therapeutics Analysis
Several major pharma and biotech companies are developing therapies Duchenne Muscular Dystrophy. Currently, Roche is leading the therapeutic market with its Duchenne Muscular Dystrophy drug candidates in the most advanced stage of clinical development.
Key Companies in the Duchenne Muscular Dystrophy Therapeutics Market Include:
• Antisense Therapeutics
• Capricor
• Daiichi Sankyo
• EDG 5506 Edgewise Therapeutics
• ENCell
• FibroGen
• Fordadistrogene movaparvovec
• Hansa Biopharma
• Italfarmaco
• Nippon Shinyaku
• Pfizer
• PTC Therapeutics
• ReveraGen BioPharma
• Sarepta Therapeutics, Inc.
• Solid Biosciences
• Taiho Pharmaceutical
• Wave Life Sciences Ltd
And Many Others
Duchenne Muscular Dystrophy Emerging Drugs
• Amondys 45: Sarepta Therapeutics
• BLS-M22: Bioleaders Corporation
• CAP 1002: Capricor
• CRISPR/Cas9 gene editing therapy: Vertex Pharmaceuticals
• DS-5141: Daiichi Sankyo
• Emflaza: PTC Therapeutics
• Exondys 51: Sarepta Therapeutics
• Givinostat: Italfarmaco
• MA-0211: Mitobridge
• Pamrevlumab: Fibrogen
• PF-06939926: Pfizer
• Pizuglanstat (TAS-205): Taiho Pharmaceutical
• TAS-205: Taiho Pharmaceutical
• Translarna: PTC Therapeutics
• Vamorolone: Santhera Pharmaceuticals/ReveraGen BioPharma
• Viltepso: Nippon Shinyaku
• Vyondys 53 (Golodirsen): Sarepta Therapeutics
• WVE N531: WaVe life Sciences
And Many More
Get an in-depth Assessment of the Emerging Therapies and Key Companies:
https://www.delveinsight.com/sample-request/duchenne-muscular-dystrophy-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr
Table of Content
1. Report Introduction
2. Executive Summary
3. Duchenne Muscular Dystrophy Current Treatment Patterns
4. Duchenne Muscular Dystrophy - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. Duchenne Muscular Dystrophy Late-Stage Products (Phase-III)
7. Duchenne Muscular Dystrophy Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Duchenne Muscular Dystrophy Discontinued Products
13. Duchenne Muscular Dystrophy Product Profiles
14. Duchenne Muscular Dystrophy Key Companies
15. Duchenne Muscular Dystrophy Key Products
16. Dormant and Discontinued Products
17. Duchenne Muscular Dystrophy Unmet Needs
18. Duchenne Muscular Dystrophy Future Perspectives
19. Duchenne Muscular Dystrophy Analyst Review
20. Appendix
21. Report Methodology
Get Detailed Insights About the Reports Offerings:
https://www.delveinsight.com/sample-request/duchenne-muscular-dystrophy-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr
Contact Info:
Shruti Thakur
Manager - Marketing & International Branding
Email: info@delveinsight.com
428, D21 Corporate Park, Sector-21, Dwarka, New Delhi-110077, India
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Duchenne Muscular Dystrophy Pipeline Assessment (2023 Updates) | In-depth Insights into the Clinical Trials, Emerging Drugs, Latest FDA, EMA, and PMDA Approvals, Competitive Landscape, and Treatment Outlook | Key Companies - Sarepta, Bioleaders Corporatio here
News-ID: 3012029 • Views: …
More Releases from DelveInsight Business Research LLP
Pharmaceutical Contract Manufacturing Market Forecast Report 2032: Size, Share, …
DelveInsight's Pharmaceutical Contract Manufacturing Market Insights Report 2032 provides the current and forecast market analysis, individual leading Pharmaceutical Contract Manufacturing Companies market shares, challenges, Pharmaceutical Contract Manufacturing Market Drivers, barriers, trends, and key market Pharmaceutical Contract Manufacturing companies in the market.
To read more about the latest highlights related to the Pharmaceutical Contract Manufacturing Market, get a snapshot of the key highlights entailed in the Market Report @ https://www.delveinsight.com/sample-request/pharmaceutical-contract-manufacturing-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Key…
Pharmaceuticals Market Forecast Report 2032: Size, Share, and Strategic Insights …
DelveInsight's Pharmaceuticals Market Insights Report 2032 provides the current and forecast market analysis, individual leading Pharmaceuticals Companies market shares, challenges, Pharmaceuticals Market Drivers, barriers, trends, and key market Pharmaceuticals companies in the market.
To read more about the latest highlights related to the Pharmaceuticals Market, get a snapshot of the key highlights entailed in the Market Report @ https://www.delveinsight.com/sample-request/pharmaceutical-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Key Takeaways from the Pharmaceuticals Market Report
• In July 2025, Sanofi announced the…
Checkpoint Inhibitors Competitive Landscape Report 2025: Emerging Therapies, Lea …
DelveInsight's, "Checkpoint Inhibitors Competitive landscape 2025" report provides comprehensive insights about 50+ companies and 60+ drugs in Checkpoint Inhibitors Competitive landscape. It covers the Checkpoint Inhibitors Therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore the full insights into the evolving Checkpoint Inhibitors Pipeline and discover which companies are leading the innovation race @ Checkpoint Inhibitors Competitive…
Surgical Simulation Market Forecast Report 2032: Size, Share, and Strategic Insi …
DelveInsight's Surgical Simulation Market Insights Report 2032 provides the current and forecast market analysis, individual leading Surgical Simulation Companies market shares, challenges, Surgical Simulation Market Drivers, barriers, trends, and key market Surgical Simulation companies in the market.
To read more about the latest highlights related to the Surgical Simulation Market, get a snapshot of the key highlights entailed in the Market Report @ https://www.delveinsight.com/sample-request/surgical-simulation-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Key Takeaways from the Surgical Simulation Market…
More Releases for Duchenne
Duchenne Muscular Dystrophy: Core Growth Enabler in the Rising Prevalence Of Chr …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
What Will the Duchenne Muscular Dystrophy Industry Market Size Be by 2025?
The market size for Duchenne Muscular Dystrophy has shown significant expansion recently, burgeoning from $1.16 billion in 2024 to $1.25 billion in 2025 at a compound annual growth rate (CAGR) of 7.9%. The impressive growth in the…
Emerging Trends Influencing The Growth Of The Duchenne Muscular Dystrophy (DMD) …
The Duchenne Muscular Dystrophy (DMD) Therapeutics Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories].
How Big Is the Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size Expected to Be by 2034?
In recent times, the market size for Duchenne Muscular Dystrophy (DMD) therapeutics has seen a significant…
Shaping the Duchenne Muscular Dystrophy (DMD) Therapeutics Market in 2025: Bit B …
How Big Is the Duchenne Muscular Dystrophy (DMD) Therapeutics Market Expected to Be, and What Will Its Growth Rate Be?
The Duchenne muscular dystrophy (DMD) therapeutics market will grow from $11.95 billion in 2024 to $16.45 billion in 2025, at a CAGR of 37.6%. The growth is attributed to the increasing prevalence of Duchenne muscular dystrophy, rising awareness of treatment options, healthcare spending, and government initiatives.
The Duchenne muscular dystrophy (DMD) therapeutics…
Duchenne Muscular Dystrophy Pipeline Outlook Report 2024
DelveInsight's, "Duchenne Muscular Dystrophy Pipeline Insight 2024" report provides comprehensive insights about 75+ companies and 75+ pipeline drugs in the Duchenne Muscular Dystrophy pipeline landscape. It covers the Duchenne Muscular Dystrophy pipeline drug profiles, including Duchenne Muscular Dystrophy clinical trials and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
…
Duchenne Muscular Dystrophy Treatmcent Market
Global Duchenne Muscular Dystrophy Treatmcent Market Set for Robust Growth During Forecast Period
The global Duchenne Muscular Dystrophy Treatment Market is poised to witness significant growth at a high Compound Annual Growth Rate (CAGR) during the forecast period of 2023 to 2030. Duchenne muscular dystrophy (DMD) stands as a genetic disorder marked by progressive muscle degeneration and weakness, with therapeutics aimed at addressing the absence of dystrophin, a crucial protein in…
Duchenne Muscular Dystrophy (DMD) Drugs Market Report
As per the research conducted by GME, the Duchenne Muscular Dystrophy (DMD) Drugs Market will grow with a CAGR value of 41.3 percent by 2026. The global market for Duchenne muscular dystrophy is foreseen to grow due to accelerated research and development activities, expanded patient awareness for effective treatments, and the launch of new medications Moreover, the disease's increasing prominence is likely to drive the global duchenne muscular dystrophy market…
